These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 30956799)

  • 1. The King's Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference.
    Sinha A; Patel AS; Siegert RJ; Bajwah S; Maher TM; Renzoni EA; Wells AU; Higginson IJ; Birring SS
    BMJ Open Respir Res; 2019; 6(1):e000363. PubMed ID: 30956799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. King's Brief Interstitial Lung Disease questionnaire: responsiveness and minimum clinically important difference.
    Nolan CM; Birring SS; Maddocks M; Maher TM; Patel S; Barker RE; Jones SE; Walsh JA; Wynne SC; George PM; Man WD
    Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31221807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The minimal important difference of the King's Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung disease.
    Patel AS; Siegert RJ; Keir GJ; Bajwah S; Barker RD; Maher TM; Renzoni EA; Wells AU; Higginson IJ; Birring SS
    Respir Med; 2013 Sep; 107(9):1438-43. PubMed ID: 23867809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rasch analysis and impact factor methods both yield valid and comparable measures of health status in interstitial lung disease.
    Patel AS; Siegert RJ; Bajwah S; Brignall K; Gosker HR; Moxham J; Maher TM; Renzoni EA; Wells AU; Higginson IJ; Birring SS
    J Clin Epidemiol; 2015 Sep; 68(9):1019-27. PubMed ID: 26004514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responsiveness and minimal clinically important difference of SGRQ-I and K-BILD in idiopathic pulmonary fibrosis.
    Prior TS; Hoyer N; Hilberg O; Shaker SB; Davidsen JR; Bendstrup E
    Respir Res; 2020 Apr; 21(1):91. PubMed ID: 32316976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of a Dyspnea Visual Analog Scale in Fibrotic Interstitial Lung Disease.
    Bevanda L; Mok V; Lin K; Assayag D; Fisher JH; Johannson KA; Khalil N; Kolb M; Manganas H; Marcoux V; Sadatsafavi M; Wong AW; Ryerson CJ
    Ann Am Thorac Soc; 2024 Jul; 21(7):1007-1014. PubMed ID: 38315632
    [No Abstract]   [Full Text] [Related]  

  • 7. The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases.
    Birring SS; Bushnell DM; Baldwin M; Mueller H; Male N; Rohr KB; Inoue Y
    Eur Respir J; 2022 Jun; 59(6):. PubMed ID: 34764181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes to assess dyspnoea in interstitial lung disease and pulmonary hypertension: a systematic literature review of measurement properties.
    Lemmers JMJ; Vonk MC; van den Ende CHM
    Eur Respir Rev; 2022 Dec; 31(166):. PubMed ID: 36543348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of the King's Brief Interstitial Lung Disease questionnaire in Idiopathic Pulmonary Fibrosis.
    Prior TS; Hilberg O; Shaker SB; Davidsen JR; Hoyer N; Birring SS; Bendstrup E
    BMC Pulm Med; 2019 Dec; 19(1):255. PubMed ID: 31856786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visual analogue scales for interstitial lung disease: a prospective validation study.
    Yates H; Adamali HI; Maskell N; Barratt S; Sharp C
    QJM; 2018 Aug; 111(8):531-539. PubMed ID: 29788503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire.
    Patel AS; Siegert RJ; Brignall K; Gordon P; Steer S; Desai SR; Maher TM; Renzoni EA; Wells AU; Higginson IJ; Birring SS
    Thorax; 2012 Sep; 67(9):804-10. PubMed ID: 22555278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of health-related quality of life decline in interstitial lung disease.
    Maqhuzu PN; Szentes BL; Kreuter M; Bahmer T; Kahn N; Claussen M; Holle R; Schwarzkopf L
    Health Qual Life Outcomes; 2020 Oct; 18(1):334. PubMed ID: 33032602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the Minimal Clinically Important Difference of the King's Sarcoidosis Questionnaire in a Multicenter Prospective Study.
    Baughman RP; Judson MA; Beaumont JL; Maier LA; Sweiss NJ; Culver DA; Chen ES; Singh N; Lower EE; Reeves R; Hamzeh N; Grutters JC; Valeyre D; Birring SS
    Ann Am Thorac Soc; 2021 Mar; 18(3):477-485. PubMed ID: 32970455
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial.
    Visca D; Mori L; Tsipouri V; Fleming S; Firouzi A; Bonini M; Pavitt MJ; Alfieri V; Canu S; Bonifazi M; Boccabella C; De Lauretis A; Stock CJW; Saunders P; Montgomery A; Hogben C; Stockford A; Pittet M; Brown J; Chua F; George PM; Molyneaux PL; Margaritopoulos GA; Kokosi M; Kouranos V; Russell AM; Birring SS; Chetta A; Maher TM; Cullinan P; Hopkinson NS; Banya W; Whitty JA; Adamali H; Spencer LG; Farquhar M; Sestini P; Wells AU; Renzoni EA
    Lancet Respir Med; 2018 Oct; 6(10):759-770. PubMed ID: 30170904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing health status over time: impact of recall period and anchor question on the minimal clinically important difference of copd health status tools.
    Alma HJ; de Jong C; Jelusic D; Wittmann M; Schuler M; Kollen BJ; Sanderman R; Schultz K; Kocks JWH; Van der Molen T
    Health Qual Life Outcomes; 2018 Jun; 16(1):130. PubMed ID: 29940980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinical study to monitor prescription patterns, clinical outcomes, and adverse drug reactions among patients of various interstitial lung diseases attending respiratory medicine outpatient department at tertiary care hospital in Northern India.
    Hasan S; Verma A; Haque S; Asif F; Nath R; Kant S; Dixit RK
    Perspect Clin Res; 2024; 15(3):141-146. PubMed ID: 39140017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal clinically important difference of the King's Parkinson's disease Pain Scale.
    Taghizadeh G; Fereshtehnejad SM; Goudarzi S; Jamali S; Mehdizadeh M
    Disabil Rehabil; 2023 May; 45(10):1680-1683. PubMed ID: 35549801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translation and validation of the King's Brief Interstitial Lung Disease (K-BILD) questionnaire in French, Italian, Swedish, and Dutch.
    Wapenaar M; Patel AS; Birring SS; Domburg RTV; Bakker EW; Vindigni V; Sköld CM; Cottin V; Vancheri C; Wijsenbeek MS
    Chron Respir Dis; 2017 May; 14(2):140-150. PubMed ID: 28019103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data.
    Basra MK; Salek MS; Camilleri L; Sturkey R; Finlay AY
    Dermatology; 2015; 230(1):27-33. PubMed ID: 25613671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic characteristics associated with slow gait speed in idiopathic pulmonary fibrosis.
    Nolan CM; Maddocks M; Maher TM; Canavan JL; Jones SE; Barker RE; Patel S; Jacob J; Cullinan P; Man WD
    Respirology; 2018 May; 23(5):498-506. PubMed ID: 29139195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.